In this context, one of the first studies conducted by Valis et al. [167], showed a significant increase in Aβ42 in the CSF of MS patients; however, no difference related to total and phosphorylated Tau protein levels was observed. The gene discussed is MAPT; the disease is myeloid sarcoma.